12 September 2023 Scandion Oncology appoints Lars Damstrup, MD, PhD, as new Chief Medical Officer Download Presentation Webcast Workbook
18 July 2023 The European Patent Office announces intention to grant of Composition-of-Matter patent for Scandion Oncology’s lead compound SCO-101 Download Presentation Webcast Workbook
31 March 2023 Scandion Oncology successfully completes the dose finding with lead compound SCO-101 in advanced pancreatic cancer patients (PANTAX phase Ib trial) Download Presentation Webcast Workbook
1 December 2022 Scandion Oncology appoints Francois Martelet, M.D., as new Chief Executive Officer Download Presentation Webcast Workbook
30 September 2022 Scandion Oncology announce topline results from part 2 of the CORIST phase II trial Download Presentation Webcast Workbook
31 August 2022 Bo Rode Hansen is leaving the position as President and CEO of Scandion Oncology Download Presentation Webcast Workbook
30 August 2022 Scandion Oncology announce change to its Executive Management Download Presentation Webcast Workbook
17 August 2022 Scandion Oncology extends PANTAX trial due to better-than-expected tolerability of SCO-101 Download Presentation Webcast Workbook
1 July 2022 Scandion Oncology announces preliminary outcome of its rights issue Download Presentation Webcast Workbook
1 June 2022 Scandion Oncology resolves on a Rights Issue of approximately SEK 93.7 million Download Presentation Webcast Workbook
8 September 2021 Scandion Oncology provides a clear path to market for SCO-101 at today’s Capital Markets Day Download Presentation Webcast Workbook